spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  gout  

 HSMN NewsFeed - 15 Dec 2025
Sobi to Acquire Arthrosi Therapeutics, Strengthening Pipeline for the Potential Treatment of Gout
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Jan 2024
ZWI Therapeutics, Inc. Announces a Series A Financing, Two Accomplished Biopharmaceutical CEOs Join the Board of Directors, and Appointment of Chief Executive Officer
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 6 Oct 2023
Amgen Completes Acquisition of Horizon Therapeutics plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2021
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jul 2020
HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 May 2020
Acquist Therapeutics Announces New Appointments to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2019
HemoShear Therapeutics Names Biopharma Veteran Kathleen M. Metters, PhD, to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2018
Grünenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Apr 2018
Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2018
Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO
Devices Surgery FDA
 HSMN NewsFeed - 15 Nov 2017
Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 1 Sep 2017
Mark Fladrich Takes Office as the New CCO of the Grünenthal Group
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2015
Selecta Announces $38 Million Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Sep 2015
Selecta Biosciences Appoints Earl E. Sands, MD, as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2014
Selecta Announces More than $20 Million in Equity Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Dec 2012
Savient Announces the Election of Robert G. Savage to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2012
Savient Receives Positive CHMP Opinion for KRYSTEXXA(R) Approval in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2012
Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2012
AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Apr 2012
Takeda to Acquire URL Pharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Mar 2012
Savient Announces Named Patient Programme for KRYSTEXXA(R) in the European Union for Patients with Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 6 Jan 2012
Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 3 Nov 2011
Savient Pharmaceuticals Receives J-code for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 6 Sep 2011
Savient Announces the Election of William F. Owen, Jr., M.D. and David Y. Norton to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jul 2011
Savient Pharmaceuticals Names Rheumatology Veteran Kenneth M. Bahrt, M.D. Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Apr 2011
Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Feb 2011
Savient Pharmaceuticals Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2011
Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2011
Savient Pharmaceuticals Provides Business Update
Biopharmaceuticals
 HSMN NewsFeed - 13 May 2010
Nuon Therapeutics Names Lee Rauch Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2010
Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Oct 2009
FDA Approves Colcrys(TM) (colchicine, USP) for Prevention of Gout Flares
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jul 2009
Allostera Pharma Inc. Closes $17M (CAD) Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jun 2009
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2009
ULORIC(R) (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2009
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jan 2009
Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Oct 2008
Savient Submits Biologics License Application (BLA) for pegloticase
Biopharmaceuticals
 HSMN NewsFeed - 13 May 2008
Siemens Introduces Dual Energy Applications for General Imaging
Devices Radiology
 HSMN NewsFeed - 5 May 2008
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Mar 2008
Siemens Introduces New Dual Energy Applications to SOMATOM Definition
Devices Radiology
 HSMN NewsFeed - 28 Feb 2008
Savient Provides Further Information on Top Line Phase 3 Trials Results for Puricase(R) (pegloticase)
Biopharmaceuticals
 HSMN NewsFeed - 21 Feb 2008
EMEA Recommends Marketing Authorisation of Ipsen's Adenuric(R) (Febuxostat) for the Treatment of Chronic Hyperuricaemia in Gout
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Dec 2007
New Drug Application for Tolvaptan, Otsuka's Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Dec 2007
Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2007
Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2007
FDA Issues Second Approvable Letter for Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Trexima(TM) (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Mar 2007
Savient Announces Completion of Patient Enrollment in Phase 3 Trials of Puricase(R) for Treatment-Failure Gout
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
POZEN Submits Full Response to FDA Approvable Letter For Trexima(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Oct 2006
Ipsen: EMEA's Validation of Febuxostat's Marketing Authorization Application in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Sep 2006
New Analysis Shows Patients Who Treat Their Migraine Pain Early With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Have Higher Sustained Pain-Free Rates Than Those Who Treat Late
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Data Show Consistent Efficacy and Tolerability of Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Across Multiple Migraine Attacks
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2006
New Data Show Peak Concentration of Sumatriptan Occurred Earlier With Trexima(TM) (Sumatriptan Succinate/Naproxen Sodium) Compared to Imitrex(R) (Sumatriptan Succinate)
Biopharmaceuticals
 HSMN NewsFeed - 6 Jul 2006
Savient Appoints Chief Financial Officer and Treasurer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
gout
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!